Caredx, Inc. (CDNA)

$29.73

+0.86

(+2.98%)▲

Market is closed - opens 7 PM, 17 Sep 2024

Performance

  • $28.41
    $29.95
    $29.73
    downward going graph

    4.44%

    Downside

    Day's Volatility :5.13%

    Upside

    0.72%

    downward going graph
  • $4.80
    $34.84
    $29.73
    downward going graph

    83.85%

    Downside

    52 Weeks Volatility :86.22%

    Upside

    14.67%

    downward going graph

Returns

PeriodCaredx, Inc.
3 Months
119.57%
6 Months
200.61%
1 Year
275.85%
3 Years
-56.26%

Highlights

Market Capitalization
1.5B
Book Value
$5.03
Earnings Per Share (EPS)
-2.98
PEG Ratio
-0.12
Wall Street Target Price
32.71
Profit Margin
-53.73%
Operating Margin TTM
-4.37%
Return On Assets TTM
-9.81%
Return On Equity TTM
-47.66%
Revenue TTM
297.1M
Revenue Per Share TTM
5.62
Quarterly Revenue Growth YOY
31.3%
Gross Profit TTM
209.6M
EBITDA
-62.4M
Diluted Eps TTM
-2.98
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
0.25
EPS Estimate Next Year
0.35
EPS Estimate Current Quarter
-0.14
EPS Estimate Next Quarter
-0.11

Analyst Recommendation

Buy
    69%Buy
    30%Hold
    0
    0%Sell
Based on 13 Wall street analysts offering stock ratings for Caredx, Inc.(by analysts ranked 0 to 5 stars)
Based on 13 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
9
9
9
Hold
4
4
4
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 10.02%

Current $29.73
Target $32.71

Company Financials

FY18Y/Y Change
Revenue
76.6M
↑ 58.45%
Net Income
-46.8M
↓ 15.71%
Net Profit Margin
-61.06%
↑ 53.73%
FY19Y/Y Change
Revenue
127.1M
↑ 65.95%
Net Income
-22.0M
↓ 53.02%
Net Profit Margin
-17.29%
↑ 43.77%
FY20Y/Y Change
Revenue
192.2M
↑ 51.25%
Net Income
-18.7M
↓ 14.81%
Net Profit Margin
-9.74%
↑ 7.55%
FY21Y/Y Change
Revenue
296.4M
↑ 54.22%
Net Income
-30.7M
↑ 63.85%
Net Profit Margin
-10.34%
↓ 0.6%
FY22Y/Y Change
Revenue
321.8M
↑ 8.57%
Net Income
-76.6M
↑ 149.86%
Net Profit Margin
-23.81%
↓ 13.47%
FY23Y/Y Change
Revenue
280.3M
↓ 12.89%
Net Income
-190.3M
↑ 148.37%
Net Profit Margin
-67.88%
↓ 44.07%
Q1 FY23Q/Q Change
Revenue
77.3M
↓ 6.22%
Net Income
-23.7M
↑ 29.57%
Net Profit Margin
-30.74%
↓ 8.49%
Q2 FY23Q/Q Change
Revenue
70.3M
↓ 9.01%
Net Income
-25.0M
↑ 5.07%
Net Profit Margin
-35.49%
↓ 4.75%
Q3 FY23Q/Q Change
Revenue
67.2M
↓ 4.42%
Net Income
-23.5M
↓ 5.88%
Net Profit Margin
-34.95%
↑ 0.54%
Q4 FY23Q/Q Change
Revenue
65.6M
↓ 2.42%
Net Income
-118.1M
↑ 402.86%
Net Profit Margin
-180.11%
↓ 145.16%
Q1 FY24Q/Q Change
Revenue
72.0M
↑ 9.88%
Net Income
-16.7M
↓ 85.89%
Net Profit Margin
-23.12%
↑ 156.99%
Q2 FY24Q/Q Change
Revenue
92.3M
↑ 28.07%
Net Income
-1.4M
↓ 91.63%
Net Profit Margin
-1.51%
↑ 21.61%
FY18Y/Y Change
Total Assets
130.7M
↑ 56.4%
Total Liabilities
34.8M
↓ 61.16%
FY19Y/Y Change
Total Assets
151.7M
↑ 16.1%
Total Liabilities
52.7M
↑ 51.68%
FY20Y/Y Change
Total Assets
368.5M
↑ 142.86%
Total Liabilities
90.8M
↑ 72.24%
FY21Y/Y Change
Total Assets
566.6M
↑ 53.76%
Total Liabilities
100.7M
↑ 10.91%
FY22Y/Y Change
Total Assets
543.0M
↓ 4.17%
Total Liabilities
112.1M
↑ 11.25%
FY23Y/Y Change
Total Assets
484.6M
↓ 10.75%
Total Liabilities
223.3M
↑ 99.22%
Q1 FY23Q/Q Change
Total Assets
528.2M
↓ 2.72%
Total Liabilities
108.2M
↓ 3.47%
Q2 FY23Q/Q Change
Total Assets
514.8M
↓ 2.54%
Total Liabilities
109.6M
↑ 1.3%
Q3 FY23Q/Q Change
Total Assets
501.2M
↓ 2.65%
Total Liabilities
107.0M
↓ 2.34%
Q4 FY23Q/Q Change
Total Assets
484.6M
↓ 3.31%
Total Liabilities
223.3M
↑ 108.59%
Q1 FY24Q/Q Change
Total Assets
452.4M
↓ 6.65%
Total Liabilities
196.2M
↓ 12.14%
Q2 FY24Q/Q Change
Total Assets
466.8M
↑ 3.18%
Total Liabilities
202.1M
↑ 3.02%
FY18Y/Y Change
Operating Cash Flow
-4.0M
↓ 71.99%
Investing Cash Flow
-7.9M
↑ 28.63%
Financing Cash Flow
50.3M
↑ 71.1%
FY19Y/Y Change
Operating Cash Flow
-2.8M
↓ 30.9%
Investing Cash Flow
-22.6M
↑ 184.76%
Financing Cash Flow
-132.0K
↓ 100.26%
FY20Y/Y Change
Operating Cash Flow
33.4M
↓ 1307.33%
Investing Cash Flow
-100.4M
↑ 344.63%
Financing Cash Flow
163.1M
↓ 123697.73%
FY21Y/Y Change
Operating Cash Flow
-19.3M
↓ 157.71%
Investing Cash Flow
47.7M
↓ 147.52%
Financing Cash Flow
185.6M
↑ 13.79%
FY22Y/Y Change
Operating Cash Flow
-25.2M
↑ 30.81%
Investing Cash Flow
-228.5M
↓ 578.92%
Financing Cash Flow
-4.5M
↓ 102.44%
Q1 FY23Q/Q Change
Operating Cash Flow
671.0K
↓ 90.66%
Investing Cash Flow
-14.8M
↓ 696.81%
Financing Cash Flow
-1.1M
↓ 52.02%
Q2 FY23Q/Q Change
Operating Cash Flow
-499.0K
↓ 174.37%
Investing Cash Flow
15.3M
↓ 203.91%
Financing Cash Flow
-1.6M
↑ 37.61%

Technicals Summary

Sell

Neutral

Buy

Caredx, Inc. is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Caredx, Inc.
Caredx, Inc.
-12.53%
200.61%
275.85%
-56.26%
26.73%
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
2.9%
-3.48%
13.57%
-22.72%
88.1%
Agilent Technologies Inc.
Agilent Technologies Inc.
-1.57%
-5.33%
22.73%
-20.48%
81.03%
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
1.08%
5.88%
20.96%
2.91%
109.82%
Danaher Corp.
Danaher Corp.
1.75%
9.77%
22.69%
-14.94%
93.94%
Iqvia Holdings Inc.
Iqvia Holdings Inc.
-1.53%
-5.98%
14.34%
-6.88%
56.52%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Caredx, Inc.
Caredx, Inc.
NA
NA
-0.12
0.25
-0.48
-0.1
NA
5.03
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
49.75
49.75
5.36
10.51
0.63
0.23
NA
19.16
Agilent Technologies Inc.
Agilent Technologies Inc.
28.58
28.58
2.96
5.24
0.25
0.08
0.01
20.53
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
37.89
37.89
2.26
21.74
0.14
0.05
0.0
124.17
Danaher Corp.
Danaher Corp.
50.46
50.46
2.73
7.58
0.08
0.04
0.0
68.92
Iqvia Holdings Inc.
Iqvia Holdings Inc.
30.97
30.97
1.17
11.2
0.23
0.05
NA
36.83
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Caredx, Inc.
Caredx, Inc.
Buy
$1.5B
26.73%
NA
-53.73%
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
Buy
$42.1B
88.1%
49.75
22.34%
Agilent Technologies Inc.
Agilent Technologies Inc.
Buy
$39.7B
81.03%
28.58
21.75%
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
Buy
$234.6B
109.82%
37.89
14.69%
Danaher Corp.
Danaher Corp.
Buy
$199.4B
93.94%
50.46
17.83%
Iqvia Holdings Inc.
Iqvia Holdings Inc.
Buy
$43.6B
56.52%
30.97
9.39%

Institutional Holdings

  • ARK Investment Management LLC

    10.81%

  • BlackRock Inc

    10.02%

  • Vanguard Group Inc

    8.31%

  • Bellevue Group AG

    7.42%

  • Sumitomo Mitsui Trust Holdings Inc

    4.88%

  • Nikko Asset Management Americas Inc

    4.88%

Company Information

caredx: transforming transplant patient care through novel surveillance management solutions caredx, inc. is dedicated to improving the lives of organ transplant patients through non-invasive diagnostics. by combining the latest advances in genomics and bioinformatics technology, with a commitment to generating high quality clinical evidence through trials and registries, caredx is at the forefront of organ transplant surveillance and pre-transplant hla typing solutions. nasdaq:cdna about allosure® allosure is the first and only non-invasive blood test that directly measures allograft injury and identifies the probability of active rejection to better manage kidney transplant patients. allosure is a clinical-grade, proprietary next-generation sequencing (ngs) based test to detect donor-derived cell-free dna (dd-cfdna) in order to identify organ injury in kidney transplant recipients. allosure is analytically validated as a sensitive, specific, and precise measurement of dd-cfdna. allos

Organization
Caredx, Inc.
Employees
635
CEO
Dr. Peter Maag Ph.D.
Industry
Health Technology

Discover More

FAQs